Latest stories on PRAX
3 ‘Strong Buy’ High-Risk Stocks with Double-Gain Potential
TipRanks64 · neutralanalyst
Praxis Precision management to meet with Piper Sandler
The Fly56 · neutralgeneral
Praxis Precision initiated with an Overweight at JPMorgan
The Fly63 · neutralanalyst
Praxis Precision initiated with a Buy at UBS
The Fly64 · neutralanalyst
Praxis Precision price target raised to $826 from $810 at BTIG
The Fly63 · neutralanalyst
LPL Financial Welcomes Praxis Financial Partners
Business Insider63 · neutralgeneral
LPL Financial Welcomes Praxis Financial Partners
GlobeNewswire56 · neutralgeneral
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Praxis Precision Medicine options signal ahead of two FDA decisions
Investing.com Markets58 · neutralgeneral
H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential
Investing.com Analyst Ratings56 · neutralanalyst
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
Seeking Alpha63 · neutralanalyst
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead
Barron's38 · neutralgeneral
Praxis Precision price target raised to $575 from $470 at Goldman Sachs
The Fly69 · bullishanalyst
Praxis Precision price target raised to $945 from $765 at Raymond James
The Fly69 · bullishanalyst
Raymond James raises Praxis Precision Medicines price target on pipeline outlook
Investing.com Analyst Ratings61 · neutralanalyst
Praxis (PRAX) Q2 2026 Earnings Call Transcript
The Motley Fool67 · bullishearnings
Praxis: Commercial Launch Could Smash Expectations (Video)
Seeking Alpha73 · bullishproduct/pr
Praxis Precision Price Target Raised To 462 From 449 At Rbc Capital
The Fly63 · neutralanalyst
Praxis signals two FDA decisions in ~six months, targets ~$10B ulixacaltamide peak sales while building a ~300-person field force
Seeking Alpha67 · bullishproduct/pr
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings